Cyrus Harmon compensation by year
Olema Pharmaceuticals Summary Compensation Table · all 3 fiscal years held| Component | FY2019 | FY2020 | FY2023 |
|---|---|---|---|
| Salary | $300,000 | $395,833 | $120,972 |
| Bonus | $0 | $0 | — |
| Stock awards | — | $344,046 | — |
| Option awards | — | $2,974,853 | $550,180 |
| Non-equity incentive | — | $262,158 | $48,000 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $0 | $0 | $615,678 |
| Total | $300,000 | $3,976,890 | $1,334,830 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Olema Pharmaceuticals, Inc. DEF 14A filed April 26, 2024, accession 0000950170-24-049287, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Olema Pharmaceuticals, Inc. filed document, accession 0000950170-24-049287. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 29,250 | $410,378 | — |
| RSU | 17,934 | $251,614 | — |
| Option | 41,099 | — | $19.00 |
| Option | 150,000 | — | $4.87 |
| Option | 150,000 | — | $4.87 |
| Option | 42,724 | — | $4.82 |
| Option | 56,605 | — | $7.02 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Olema Pharmaceuticals, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
11 Form 4 lines since the FY2023 proxy (filed April 26, 2024)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-07-24 | Sale | — | 12,500 | $11.71 | 702,770 |
| 2026-07-23 | Sale | — | 12,500 | $11.58 | 715,270 |
| 2026-06-18 | Grant or award derivative | — | 29,500 | $0.00 | 29,500 |
| 2026-01-20 | Sale | — | 10,000 | $26.88 | 727,770 |
| 2026-01-14 | Sale | — | 3,489 | $29.12 | 737,770 |
| 2025-12-22 | Sale | — | 2,881 | $28.53 | 741,259 |
| 2025-09-18 | Sale | — | 10,000 | $8.33 | 744,140 |
| 2025-09-18 | Sale | — | 3,086 | $8.32 | 117,028 |
The 8 most recent of 11 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Olema Pharmaceuticals’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Sean Bohen | President and Chief Executive Officer | $3,152,370 |
| Shane Kovacs | Chief Operating and Financial Officer | $1,548,370 |
| Cyrus Harmon · this page | Former Chief Research Officer and Former Chief Executive Officer | $1,334,830 |
| Naseem Zojwalla | Chief Medical Officer | $1,299,370 |
Board service
Olema Pharmaceuticals board · FY2024–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $43,750 | — | $65,688 | — | $109,438 |
| FY2024 | $40,000 | — | $200,790 | — | $240,790 |
Each year as the company reported it in Olema Pharmaceuticals's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Olema Pharmaceuticals pays directors a $45,000 cash retainer. As stated in Olema Pharmaceuticals's FY2025 proxy.
Committees
Science and Technology
The full Olema Pharmaceuticals compensation record
free company briefThis page is one person within Olema Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Olema Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Olema Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.